Heparin Drip vs. Eliquis in AFib with RVR and Leg Thrombus

Acute Management Considerations

For patients with AFib and RVR with hemodynamic compromise, immediate rate control is needed with IV beta-blockers or calcium channel blockers to achieve a target ventricular rate of 80-100 bpm, as recommended by the European Society of Cardiology 1
In patients with AFib and occlusive thrombus requiring immediate intervention, initial IV unfractionated heparin or LMWH should be administered before any cardioversion attempts, according to the American Heart Association 2, 1
For patients with AFib duration <48 hours and high stroke risk (including those with thrombus), IV heparin or LMWH should be initiated immediately, followed by long-term anticoagulation, as suggested by the American Heart Association 2, 3

Direct oral anticoagulants (DOACs) like apixaban are recommended over warfarin in DOAC-eligible patients with AFib (except with moderate/severe mitral stenosis or mechanical heart valves) by the American College of Cardiology 4
A meta-analysis of four major DOAC trials showed 19% reduction in stroke or systemic embolism compared to warfarin, driven by 51% reduction in hemorrhagic stroke and 10% reduction in overall mortality, as reported in the medical literature 5
For patients with AFib and occlusive thrombus, anticoagulation should be based on thromboembolic risk assessment using CHA2DS2-VASc score, as recommended by the American College of Cardiology 4

The ARISTOTLE trial demonstrated that apixaban was superior to warfarin with fewer strokes or systemic embolisms (1.27% versus 1.60%) and less bleeding (2.13% versus 3.09%) 5
Apixaban has been shown to be superior to warfarin in reducing bleeding events in the setting of acute coronary syndrome with no difference in thrombotic events, as reported in the medical literature 6
DOACs have a wider therapeutic window than heparin and don't require the frequent monitoring needed with IV heparin therapy, according to the American Heart Association 6

Heparin-induced thrombocytopenia (HIT) is a potential serious complication of heparin therapy that can result in venous or arterial thrombosis, as reported in the medical literature 7

For patients initially treated with heparin, transition to a DOAC like apixaban is recommended for long-term management by the American College of Cardiology 4, 5
If cardioversion is needed for AFib with RVR, anticoagulation should be continued for at least 4 weeks after cardioversion, with long-term anticoagulation based on stroke risk factors, as recommended by the American Heart Association 2, 3
For patients with AFib and thrombus, long-term anticoagulation is typically indicated regardless of whether sinus rhythm is maintained, according to the European Society of Cardiology 1

If the patient has mechanical heart valves, warfarin would be required instead of a DOAC, as recommended by the American College of Cardiology 4
For patients with renal impairment, dose adjustment of apixaban may be necessary, and in severe renal failure, heparin might be preferred initially, as reported in the medical literature 6
In patients at high risk for both thrombotic and bleeding complications, careful assessment of risk-benefit ratio is essential, according to the American Heart Association 6